Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS
· Delayed Price · Currency is USD
0.0289
+0.0081 (38.94%)
Apr 21, 2025, 3:34 PM EDT
Syros Pharmaceuticals Revenue
Syros Pharmaceuticals had revenue of $386.00K in the twelve months ending September 30, 2024, down -95.61% year-over-year. In the year 2023, Syros Pharmaceuticals had annual revenue of $9.94M, down -33.23%.
Revenue (ttm)
386.00K
Revenue Growth
-95.61%
P/S Ratio
1.61
Revenue / Employee
5.68K
Employees
68
Market Cap
621.17K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.94M | -4.94M | -33.23% |
| Dec 31, 2022 | 14.88M | -8.61M | -36.65% |
| Dec 31, 2021 | 23.49M | 8.40M | 55.62% |
| Dec 31, 2020 | 15.09M | 13.11M | 661.50% |
| Dec 31, 2019 | 1.98M | -68.00K | -3.32% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Syros Pharmaceuticals News
- 6 days ago - Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - Seeking Alpha
- 7 weeks ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
- 5 months ago - Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
- 5 months ago - Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression - Business Wire
- 6 months ago - The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions - Accesswire
- 6 months ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm - Accesswire
- 6 months ago - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations - Accesswire
- 6 months ago - Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript - Seeking Alpha